To join the webcast, please use this link: http://www.bizvision.com/webcast/prod/83698
The California Technology Assessment Forum (CTAF), a core program of the Institute for Clinical and Economic Review (ICER), will hold a public meeting on February 16, 2017 to discuss the comparative effectiveness and value of disease-modifying therapies for relapsing-remitting and primary-progressive multiple sclerosis.
The Institute for Clinical and Economic Review (ICER) will produce a report that includes a systematic review of the published evidence as well as an economic analysis that examines the cost-effectiveness and budget impact of multiple disease-modifying therapies for multiple sclerosis.The report will form the basis for deliberation and discussion at the public meeting, where the CTAF panel will vote on key questions raised in the reports, and a policy roundtable will discuss evidence-based practice and policy recommendations.
A list of key dates for stakeholder engagement opportunities associated with the review of diabetes prevention programs can be found on ICER's website at https://icer-review.org/meeting/multiple-sclerosis/.
A recording of the public meeting and presentation slides will be posted after the meeting.